ME/CFS Severely ill Big Data Study
Status: Sample collection completed; testing and analysis being done now.
Lead researchers: Ronald W. Davis, PhD; Andreas Kogelnik, MD, PhD.
Study information: This is the first study in our End ME/CFS Project. It includes a very extensive biological workup (genetics, genomics, pathogens, proteomics, immunology, microbiome, metabolomics) of severely ill ME/CFS patients, in whom the disease “signal” should be strongest. It will use sophisticated “big data” analysis techniques to look for molecular biomarkers to allow accurate diagnosis, and lead to effective treatments. Funding is needed to test the moderately ill patients in order to validate the findings being found in the severely ill patients. Read more about the study here.
ME/CFS Metabolomics and Genetics Study
Status: Participants selected; blood draws occurring now.
Lead researchers: Ronald W. Davis, PhD; Robert Naviaux, MD, PhD.
Study information: This is the second study in our End ME/CFS Project. The purpose of this study is to validate earlier findings of a possible diagnostic signature for ME/CFS by measuring metabolites and to evaluate the contribution of genetics to the variation in observed metabolic signatures in this disease. If validated, this molecular signature could be used in diagnosis and provide a focus for pilot treatment trials. Read more about the study here.
Effect of Supplementing With Methylfolate and Methyl B12 in Relation to MTHFR Gene Mutations
Status: Study in progress.
Lead researchers: Andreas Kogelnik, MD, PhD; David Kaufman, MD.
Study information: This study is assessing the effects of methyl B12 and methylfolate in ME/CFS patients who have certain genetic mutations.
HLA DNA Analysis of ME/CFS Patients
Status: Testing complete, analysis in progress.
Lead researchers: Researchers at the Stanford Genome Technology Center and Andreas Kogelnik, MD, PhD.
Study information: This study uses new technology (developed by Stanford) for in-depth sequencing of the HLA region of the genome, which regulates the immune system. Approximately 700 ME/CFS patients are in this study.